The KRAS oncogene, which is mutated in 15–30% of lung cancers, in 90% of pancreatic cancers and in 30–40% of colorectal cancers is one of the main driver mutations in these severe cancer forms, which are causes of significant public health burden and mortality [51–54]. Here, KRAS is linked to familial pancreatic carcinoma.